We are live on ! Find out more
AI

Allostery Investments Portfolio holdings

AUM $7.85M
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$69.3M
AUM Growth
-$26.4M
Cap. Flow
-$17.7M
Cap. Flow %
-25.58%
Top 10 Hldgs %
65.25%
Holding
56
New
16
Increased
11
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$4.49M
2
ABVX
Abivax
ABVX
+$3.44M
3
BBIO icon
BridgeBio Pharma
BBIO
+$2.7M
4
PLRX icon
Pliant Therapeutics
PLRX
+$2.68M
5
PCVX icon
Vaxcyte
PCVX
+$2.56M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$982K
2
DFTX
Definium Therapeutics
DFTX
+$905K
3
DNTH icon
Dianthus Therapeutics
DNTH
+$545K
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$496K
5
JSPR icon
Jasper Therapeutics
JSPR
+$470K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$10.4B
$6.87M 9.91%
1,099,654
+508,401
+86% +$3.44M
CNTA
2
DELISTED
Centessa Pharmaceuticals
CNTA
$5.5M 7.93%
382,524
+98,007
+34% +$1.6M
KALV
3
DELISTED
KalVista Pharmaceuticals
KALV
$5.29M 7.63%
458,302
-20,798
-4% -$212K
MRUS
4
DELISTED
Merus
MRUS
$5.25M 7.57%
124,657
+102,922
+474% +$4.49M
EOLS icon
5
Evolus
EOLS
$397M
$4.97M 7.16%
412,754
-18,363
-4% -$240K
APGE icon
6
Apogee Therapeutics
APGE
$10.1B
$4.11M 5.93%
110,000
+10,000
+10% +$387K
ALKS icon
7
Alkermes
ALKS
$8.11B
$3.8M 5.48%
115,000
-5,000
-4% -$163K
JBIO
8
Jade Biosciences
JBIO
$1.18B
$3.57M 5.15%
40,616
+16,311
+67% +$1.43M
ZURA icon
9
Zura Bio
ZURA
$504M
$3M 4.33%
2,329,384
+814,258
+54% +$1.28M
ACLX
10
DELISTED
Arcellx
ACLX
$2.89M 4.16%
44,000
+9,000
+26% +$610K
CYTK icon
11
Cytokinetics
CYTK
$10.6B
$2.81M 4.06%
70,000
+5,000
+8% +$230K
BBIO icon
12
BridgeBio Pharma
BBIO
$16.4B
$2.77M 3.99%
+80,000
New +$2.7M
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
$2.32M 3.34%
+52,500
New +$2.42M
BEAM icon
14
Beam Therapeutics
BEAM
$2.68B
$1.81M 2.61%
+92,754
New +$2.43M
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
$1.43M 2.06%
+20,000
New +$974K
PCVX icon
16
Vaxcyte
PCVX
$7.65B
$1.21M 1.74%
+32,000
New +$2.56M
IONS icon
17
Ionis Pharmaceuticals
IONS
$8.93B
$1.06M 1.52%
35,000
-30,000
-46% -$982K
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.1B
$1.01M 1.45%
30,000
– –
AMLX icon
19
Amylyx Pharmaceuticals
AMLX
$2.19B
$942K 1.36%
+266,099
New +$947K
AVTX icon
20
Avalo Therapeutics
AVTX
$1.01B
$858K 1.24%
107,141
+33,827
+46% +$256K
VRNA
21
DELISTED
Verona Pharma
VRNA
$794K 1.14%
+12,500
New +$748K
INSM icon
22
Insmed
INSM
$22.4B
$763K 1.1%
10,000
– –
AKRO
23
DELISTED
Akero Therapeutics
AKRO
$729K 1.05%
+18,000
New +$763K
TARS icon
24
Tarsus Pharmaceuticals
TARS
$2.55B
$699K 1.01%
13,600
– –
GOSS icon
25
Gossamer Bio
GOSS
$101M
$674K 0.97%
613,028
– –
1
2 3

Similar funds

CP
Castalian Partners Excelsior, Minnesota $7.36M AUM
CAWM
Capital A Wealth Management New Castle, Pennsylvania $8.94M AUM
ADIM
Alpha DNA Investment Management Columbia, Maryland $8.98M AUM 26.05% 1-Year Est. Return
PC
Prysm Capital Princeton, New Jersey $10.6M AUM 2.38% 1-Year Est. Return
AVM
Altos Ventures Management Burlingame, California $11.7M AUM 182.72% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
BPWM
Black Point Wealth Management Naples, Florida $3.5M AUM 16.42% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return

Allostery Investments's Q1 2025 Portfolio in Review

As of Q1 2025, Allostery Investments held 56 positions worth $69.3M, down 28% from $95.7M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Allostery Investments withdrew a net $17.7M in Q1 2025, closing 15 positions and reducing 5 holdings. Its most notable exit was Definium Therapeutics, an estimated $905K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 53% a quarter earlier.

Against the trend, Allostery Investments opened a new position in BridgeBio Pharma worth $2.77M.

  • Allostery Investments's largest Q1 2025 buy was BridgeBio Pharma: 80,000 shares worth $2.77M.
  • Allostery Investments added most to Merus in Q1 2025, an estimated $4.49M increase.
  • Allostery Investments's biggest Q1 2025 reduction was Ionis Pharmaceuticals, cutting an estimated $982K.
  • Allostery Investments fully exited Definium Therapeutics in Q1 2025, selling an estimated $905K.
  • Allostery Investments's ten largest holdings make up 65% of its $69.3M portfolio in Q1 2025.
  • Allostery Investments opened 16 new positions and closed 15 in Q1 2025.
  • Allostery Investments's portfolio value fell 28% quarter-over-quarter to $69.3M.

Based on Allostery Investments's 13F filing for Q1 2025, filed 15 May 2025.